Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BaselineVariablesList
.... 14.5 BookCitation
.... 14.6 BookPartCitation
.... 14.7 CertaintyOfEvidence
.... 14.8 Classification
.... 14.9 CohortDefinition
.... 14.10 Comment
.... 14.11 ComparativeBaselineMeasureEvidence
.... 14.12 ComparativeEvidence
.... 14.13 ComparativeEvidenceReport
.... 14.14 ComparativeEvidenceReportSubject
.... 14.15 ComparativeEvidenceSynthesisReport
.... 14.16 ComparativeParticipantFlowEvidence
.... 14.17 ComparatorGroup
.... 14.18 ComparatorOnlyEvidence
.... 14.19 Comparison
.... 14.20 CompositeRating
.... 14.21 ConceptualCohortDefinition
.... 14.22 ConceptualComparatorDefinition
.... 14.23 ConceptualExposureDefinition
.... 14.24 CTISRecord
.... 14.25 DatabaseCitation
.... 14.26 DatabaseEntryCitation
.... 14.27 DatasetCitation
.... 14.28 DateAsRating
.... 14.29 DichotomousIntendedOutcome
.... 14.30 EndpointAnalysisPlan
.... 14.31 EvidenceList
.... 14.32 EvidenceReport
.... 14.33 EvidenceReportPackage
.... 14.34 EvidenceReportSubject
.... 14.35 EvidenceSynthesisEvidence
.... 14.36 EvidenceTableReportPackage
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 InterventionOnlyEvidence
.... 14.42 JournalArticleCitation
.... 14.43 M11Report
.... 14.44 M11ResearchStudy
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReport
.... 14.61 ParticipantFlowVariablesList
.... 14.62 PreprintCitation
.... 14.63 Rating
.... 14.64 Recommendation
.... 14.65 RecommendationAction
.... 14.66 RecommendationEligibilityCriteria
.... 14.67 RecommendationJustification
.... 14.68 RecommendationPlan
.... 14.69 ResearchStudyDataDictionary
.... 14.70 RiskOfBias
.... 14.71 SearchResults
.... 14.72 SearchStrategy
.... 14.73 SingleStudyEvidence
.... 14.74 SoaPlanDefinition
.... 14.75 SoftwareCitation
.... 14.76 StatisticModel
.... 14.77 StudyEligibilityCriteria
.... 14.78 StudyGroup
.... 14.79 SummaryOfFindings
.... 14.80 SummaryOfNetEffect
.... 14.81 SystematicReview
.... 14.82 SystematicReviewEligibilityCriteria
.... 14.83 SystematicReviewExcludedStudies
.... 14.84 SystematicReviewIncludedStudies
.... 14.85 VariableDefinition
.... 14.86 WebPageCitation
.... 14.87 AdditionalLanguage
.... 14.88 ArtifactAssessmentCompared
.... 14.89 ArtifactAssessmentDateAsRating
.... 14.90 CharacteristicTiming
.... 14.91 CiteAs
.... 14.92 EvidenceVariableClassifier
.... 14.93 EvidenceVariableConditional
.... 14.94 EvidenceVariableConstraint
.... 14.95 EvidenceVariableDataCleaning
.... 14.96 EvidenceVariableDataStorage
.... 14.97 EvidenceVariableDefinitionModifier
.... 14.98 EvidenceVariableHandlingDetail
.... 14.99 EvidenceVariableMissingData
.... 14.100 EvidenceVariablePeriod
.... 14.101 RelatesTo
.... 14.102 RelatesToWithQuotation
.... 14.103 RelativeOutcomeImportance
.... 14.104 ResearchStudyComparisonGroupEligibility
.... 14.105 ResearchStudyExcludedStudy
.... 14.106 ResearchStudyIncludedStudy
.... 14.107 ResearchStudyNumberOfStudiesIdentified
.... 14.108 ResearchStudyNumberOfStudiesIncluded
.... 14.109 ResearchStudyOutcomeMeasure
.... 14.110 ResearchStudyResultAsComposition
.... 14.111 ResearchStudySaeReportingMethod
.... 14.112 ResearchStudySearchStrategy
.... 14.113 ResearchStudySponsorConfidentialityStatement
.... 14.114 ResearchStudyStudyAmendment
.... 14.115 ResearchStudySystematicReviewEligibilityCriteria
.... 14.116 StatisticModelExpression
.... 14.117 StatisticModelIncludeIf
.... 14.118 TargetAttachment
.... 14.119 TargetCanonical
.... 14.120 TargetMarkdown
.... 14.121 TargetReference
.... 14.122 TargetUri
.... 14.123 Evidence Report Contributor Role Value Set
.... 14.124 Recommendation Justification Classifier Codes Value Set
.... 14.125 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.126 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.127 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.128 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.129 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.130 179899
.... 14.131 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.132 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.133 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.134 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.135 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.136 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.137 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.138 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.139 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.140 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.141 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.142 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.143 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.144 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.145 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.146 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.147 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.148 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.149 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.150 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.151 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.152 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.153 27979893 6. Glycemic Targets.
.... 14.154 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.155 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.156 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.157 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.158 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.159 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.160 30467172 Finding my inner Wonder Woman.
.... 14.161 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.162 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.163 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.164 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.165 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.166 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.167 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.168 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.169 Adults with type 2 diabetes
.... 14.170 Adults with type 2 diabetes and CVD and CKD
.... 14.171 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.172 Age
.... 14.173 Age with comparator
.... 14.174 Age with intervention
.... 14.175 Aircraft Type
.... 14.176 Aircraft Type with comparator
.... 14.177 Aircraft Type with intervention
.... 14.178 Altitude
.... 14.179 Altitude comparing intervention vs. comparator
.... 14.180 Altitude for enrolled group
.... 14.181 Altitude for screened group
.... 14.182 Altitude with comparator
.... 14.183 Altitude with intervention
.... 14.184 Analyzed Group PARACHUTE Trial
.... 14.185 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.186 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.187 Baseline Measures List for PARACHUTE Trial
.... 14.188 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.189 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.190 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.191 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.192 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.193 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.194 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.195 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.196 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.197 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.198 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.199 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.200 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.201 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.202 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.203 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.204 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.205 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.206 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.207 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.208 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.209 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.210 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.211 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.212 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.213 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.214 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.215 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.216 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.217 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.218 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.219 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.220 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.221 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.222 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.223 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.224 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.225 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.226 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.227 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.228 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.229 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.230 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.231 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.232 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.233 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.234 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.235 ComparatorDefinition: Standard care
.... 14.236 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.237 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.238 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.239 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.240 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.241 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.242 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.243 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.244 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.245 Computable_Publishing_LLC
.... 14.246 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.247 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.248 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.249 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.250 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.251 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.252 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.253 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.254 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.255 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.256 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.257 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.258 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.259 ConceptualCohortDefinition: Nonfatal stroke
.... 14.260 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.261 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.262 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.263 ConceptualCohortDefinition: Severe obesity
.... 14.264 ConceptualCohortDefinition: T1DM or T2DM
.... 14.265 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.266 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.267 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.268 ConceptualCohortDefinition_Cardiovascular_event
.... 14.269 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.270 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.271 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.272 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.273 COVID_19PneumoniaHospitalizedAdult
.... 14.274 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.275 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.276 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.277 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.278 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.279 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.280 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.281 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.282 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.283 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.284 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.285 DatabaseCitation: Citation for FEvIR Platform
.... 14.286 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.287 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.288 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.289 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.290 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.291 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.292 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.293 declined randomization in PARACHUTE Study
.... 14.294 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.295 Delany-Moretlwe 2022 clinical trial
.... 14.296 Diabetes treatment medication
.... 14.297 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.298 EBMImplementationGuideProfile Value Set
.... 14.299 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.300 Eligibility criteria for NMA_Diabetes
.... 14.301 Enrolled Group PARACHUTE Trial
.... 14.302 Ethnic Group
.... 14.303 Ethnic Group with comparator
.... 14.304 Ethnic Group with intervention
.... 14.305 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.306 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.307 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.308 EvidenceReportSectionCode Value Set
.... 14.309 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.310 EvidenceVariable: case_id
.... 14.311 EvidenceVariable: Patient id
.... 14.312 EvidenceVariable: Time of measurement
.... 14.313 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.314 Excluded from PARACHUTE Study
.... 14.315 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.316 ExposureVariable: Age (as continuous variable)
.... 14.317 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.318 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.319 ExposureVariable: pht013093.v1.p1 RACE
.... 14.320 ExposureVariable: pht013093.v1.p1 SEX
.... 14.321 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.322 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.323 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.324 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.325 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.326 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.327 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.328 Family History of Parachute Use
.... 14.329 Family History of Parachute Use with comparator
.... 14.330 Family History of Parachute Use with intervention
.... 14.331 Frequent Flier
.... 14.332 Frequent Flier with comparator
.... 14.333 Frequent Flier with intervention
.... 14.334 GLP-1 RA Group in Adults with diabetes type 2 with moderate CV risk
.... 14.335 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.336 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.337 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.338 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.339 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.340 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.341 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.342 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.343 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.344 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.345 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.346 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.347 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.348 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.349 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.350 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.351 Health Survey Score Total
.... 14.352 Health Survey Score Total comparing intervention vs. comparator
.... 14.353 Health Survey Score Total with comparator
.... 14.354 Health Survey Score Total with intervention
.... 14.355 Health Survey Score-Mental Health Subscore
.... 14.356 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.357 Health Survey Score-Mental Health Subscore with comparator
.... 14.358 Health Survey Score-Mental Health Subscore with intervention
.... 14.359 Health Survey Score-Physical Health Subscore
.... 14.360 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.361 Health Survey Score-Physical Health Subscore with comparator
.... 14.362 Health Survey Score-Physical Health Subscore with intervention
.... 14.363 Height
.... 14.364 Height with comparator
.... 14.365 Height with intervention
.... 14.366 History of Acrophobia
.... 14.367 History of Acrophobia with comparator
.... 14.368 History of Acrophobia with intervention
.... 14.369 History of Broken Bones
.... 14.370 History of Broken Bones with comparator
.... 14.371 History of Broken Bones with intervention
.... 14.372 History of Parachute Use
.... 14.373 History of Parachute Use with comparator
.... 14.374 History of Parachute Use with intervention
.... 14.375 ICD-10-GM Terminale Codes
.... 14.376 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.377 Injury Severity Score 30 days after Impact with comparator
.... 14.378 Injury Severity Score 30 days after Impact with intervention
.... 14.379 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.380 Injury Severity Score on Impact with comparator
.... 14.381 Injury Severity Score on Impact with intervention
.... 14.382 International vs Domestic Flight
.... 14.383 International vs Domestic Flight with comparator
.... 14.384 International vs Domestic Flight with intervention
.... 14.385 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.386 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.387 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.388 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.389 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.390 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.391 Investigator
.... 14.392 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.393 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.394 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.395 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.396 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.397 Jumping from aircraft with empty backpack
.... 14.398 Jumping from aircraft with parachute
.... 14.399 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.400 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.401 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.402 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.403 M11 Report Template Instructions
.... 14.404 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.405 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.406 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.407 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.408 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.409 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.410 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.411 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.412 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.413 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.414 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.415 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.416 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.417 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.418 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.419 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.420 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.421 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.422 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.423 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.424 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.425 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.426 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.427 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.428 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.429 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.430 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.431 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.432 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.433 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.434 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.435 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.436 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.437 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.438 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.439 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.440 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.441 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.442 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.443 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.444 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.445 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.446 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.447 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.448 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.449 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.450 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.451 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.452 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.453 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.454 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.455 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.456 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.457 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.458 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.459 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.460 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.461 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.462 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.463 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.464 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.465 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.466 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.467 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.468 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.469 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.470 Median Age of Parachute Intervention Group
.... 14.471 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.472 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.473 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.474 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.475 Mortality at 14 days
.... 14.476 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.477 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.478 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.479 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.480 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.481 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.482 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.483 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.484 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.485 NHANES LBDGLUSI Variable Definition
.... 14.486 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.487 NHANES LBXGLU Variable Definition
.... 14.488 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.489 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.490 NHANES SEQN Respondent Sequence Number
.... 14.491 NHANES WTSAF2YR Variable Definition
.... 14.492 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.493 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.494 NT-proBNP Study Data Dictionary
.... 14.495 Organ support-free days
.... 14.496 Outcome Definition: All-cause mortality
.... 14.497 Outcome Definition: Body weight
.... 14.498 Outcome Definition: Cardiovascular mortality
.... 14.499 Outcome Definition: End-stage kidney disease
.... 14.500 Outcome Definition: Health-related quality of life
.... 14.501 Outcome Definition: Heart failure
.... 14.502 Outcome Definition: Nonfatal myocardial infarction
.... 14.503 Outcome Definition: Nonfatal stroke
.... 14.504 Outcome Definition: Serious hyperglycaemia
.... 14.505 Outcome Definition: Severe gastrointestinal events
.... 14.506 Outcome Importance Rating 100 of All-cause mortality
.... 14.507 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.508 Outcome Importance Rating 5 of New onset depression
.... 14.509 Outcome Importance Rating 5 of Remission of diabetes
.... 14.510 Outcome Importance Rating 5 of Treatment with opioids
.... 14.511 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.512 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.513 Outcome Variables List for PARACHUTE Trial
.... 14.514 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.515 Outcome: Death or Major Traumatic Injury on Impact
.... 14.516 Outcome: Injury Severity Score 30 days after Impact
.... 14.517 Outcome: Injury Severity Score on Impact
.... 14.518 OutcomeDefinition: Injury Severity Score on Impact
.... 14.519 OutcomeDefinition: All-cause mortality
.... 14.520 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.521 OutcomeDefinition: Body weight
.... 14.522 OutcomeDefinition: Cardiovascular mortality
.... 14.523 OutcomeDefinition: Diabetes in remission
.... 14.524 OutcomeDefinition: Diabetic ketoacidosis
.... 14.525 OutcomeDefinition: End-stage kidney disease
.... 14.526 OutcomeDefinition: Genital infection
.... 14.527 OutcomeDefinition: HbA1c at 12 months
.... 14.528 OutcomeDefinition: HbA1c at 24 months
.... 14.529 OutcomeDefinition: HbA1c at 36 months
.... 14.530 OutcomeDefinition: HbA1c at 6 months
.... 14.531 OutcomeDefinition: HbA1c at 60 months
.... 14.532 OutcomeDefinition: Health-related quality of life
.... 14.533 OutcomeDefinition: Heart failure
.... 14.534 OutcomeDefinition: Mortality at 14 days
.... 14.535 OutcomeDefinition: New onset depression
.... 14.536 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.537 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.538 OutcomeDefinition: Nonfatal stroke
.... 14.539 OutcomeDefinition: Serious hyperglycaemia
.... 14.540 OutcomeDefinition: Severe gastrointestinal events
.... 14.541 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.542 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.543 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.544 OutcomeVariable: HbA1c at 12 months
.... 14.545 OutcomeVariable: HbA1c at 24 months
.... 14.546 OutcomeVariable: HbA1c at 36 months
.... 14.547 OutcomeVariable: HbA1c at 6 months
.... 14.548 OutcomeVariable: HbA1c at 60 months
.... 14.549 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.550 OutcomeVariable: New onset depression
.... 14.551 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.552 OutcomeVariable: Remission of diabetes
.... 14.553 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.554 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.555 OutcomeVariable_All_cause_mortality
.... 14.556 OutcomeVariable_Treatment_with_opioids
.... 14.557 PARACHUTE Trial baseline characteristics
.... 14.558 PARACHUTE Trial non participants
.... 14.559 PARACHUTE trial participant flow report
.... 14.560 PARACHUTE Trial Participants
.... 14.561 PARACHUTE Trial Participants assigned an empty backpack
.... 14.562 PARACHUTE trial participants assigned parachute
.... 14.563 PARACHUTE Trial Participants available for randomization
.... 14.564 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.565 PARACHUTE Trial Participants randomized into groups
.... 14.566 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.567 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.568 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.569 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.570 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.571 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.572 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.573 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.574 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.575 PARACHUTE Trial Participants that declined randomization
.... 14.576 PARACHUTE Trial Participants with no contact at 30 days
.... 14.577 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.578 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.579 PARACHUTE Trial Results
.... 14.580 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.581 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.582 Participant Flow Variables List for PARACHUTE Trial
.... 14.583 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.584 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.585 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.586 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.587 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.588 ParticipantFlowMeasure: Exclusion from analysis
.... 14.589 ParticipantFlowMeasure: Inclusion in analysis
.... 14.590 Participants Excluded from PARACHUTE Study
.... 14.591 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.592 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.593 Placebo
.... 14.594 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.595 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.596 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.597 randomized into groups for PARACHUTE Trial
.... 14.598 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.599 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.600 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.601 Recommendation Justification Code System
.... 14.602 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.603 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.604 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.605 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.606 Remdesivir
.... 14.607 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.608 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.609 Risk of Bias Assessment of PARACHUTE trial
.... 14.610 Risk Of Bias Type Value Set
.... 14.611 Screened Group PARACHUTE Trial
.... 14.612 Search Strategy for NMA_Diabetes
.... 14.613 SearchResults: PubMed search for Wonder Woman
.... 14.614 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.615 SearchStrategy: PubMed search for Wonder Woman
.... 14.616 SearchStrategyCharacteristicCode Value Set
.... 14.617 Sex
.... 14.618 Sex with comparator
.... 14.619 Sex with intervention
.... 14.620 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.621 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.622 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.623 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.624 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.625 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.626 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.627 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.628 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.629 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.630 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.631 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.632 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.633 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.634 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.635 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.636 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.637 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.638 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.639 Time to integration of results in a recommendation
.... 14.640 VariableDefinition: Comparator
.... 14.641 VariableDefinition: Condition(s)
.... 14.642 VariableDefinition: Date of birth
.... 14.643 VariableDefinition: Date of measurement
.... 14.644 VariableDefinition: Gender
.... 14.645 VariableDefinition: NTproBNP
.... 14.646 VariableDefinition: Unit
.... 14.647 Velocity
.... 14.648 Velocity comparing intervention vs. comparator
.... 14.649 Velocity for enrolled group
.... 14.650 Velocity for non participant group
.... 14.651 Velocity with comparator
.... 14.652 Velocity with intervention
.... 14.653 WebPageCitation: A HEvKA Update Summary
.... 14.654 Weight
.... 14.655 Weight with comparator
.... 14.656 Weight with intervention